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Inherited platelet function disorders are associated with a heightened risk for mucocutaneous 
bleeding of variable severity and excessive hemorrhage after surgery or trauma.
1
 They are most 
commonly associated with abnormalities of receptors for adhesive proteins or soluble agonists, of 
cytoplasmic granules or of signal transduction pathways.
1
 Laboratory screening for inherited 
platelet function disorders includes measurement of platelet aggregation by light transmission 
aggregometry, induced by agonists in citrate-anticoagulated platelet-rich plasma (PRP).
1
 Platelet 
aggregation induced by adenosine diphosphate (ADP) is abnormal in many platelet function 
disorders.
1
 ADP interacts with Gq-coupled P2Y
1
 and Gi-coupled P2Y
12
 receptors, coactivation of 
which is essential for full platelet aggregation (Figure 1A).
2
 P2Y
1
 activates phospholipase Cβ-
dependent increase in cytoplasmic Ca
2+
, which stimulates platelet shape change through 
phosphorylation of myosin light chain and platelet aggregation through calcium- and 
diacylglycerol-regulated guanine exchange factor-1 (CalDAG-GEFI)-mediated stimulation of the 
small GTPase Rap1 and consequent activation of integrin αIIbβ3, which binds adhesive proteins, 
such as fibrinogen, bridging adjacent platelets together, forming a platelet aggregate (Figure 1B).
3
 
Platelet aggregation is reinforced by P2Y
12
, which, via phosphoinositide 3-kinase signaling, 
prevents Rap1 deactivation by Ras GTPase-activating protein 3 (Figure 1B).
4
 ADP-induced platelet 
aggregation is slowly reversible, but, in citrate-anticoagulated PRP, is amplified and stabilized by a 
“secondary” platelet aggregation, induced by thromboxane A
2
 and ADP secretion, when “primary” 
platelet aggregation exceeds a threshold amplitude.
5
 While abnormalities of secondary platelet 
aggregation, associated with defects of platelet granules or secretory mechanisms, are relatively 
common,
1
 platelet function disorders affecting primary platelet aggregation are rare, including 
defects of P2Y
12
,
6
 CalDAG-GEFI, reviewed by Palma-Barqueros et al.
7
, and the final common steps 
of integrin αIIbβ3 activation (Glanzmann Thrombasthenia and Leukocyte Adhesion Deficiency-III).
1
 
ADP-induced platelet aggregation is impaired in defects of P2Y
12
 or CalDAG-GEFI, while it is absent 
 3
(albeit preceded by normal platelet shape change) in Glanzmann Thromboasthenia and Leukocyte 
Adhesion Deficiency-III.
 1
 A platelet phenotype similar to that of Glanzmann Thrombasthenia and 
Leukocyte Adhesion Deficiency-III can be reproduced in normal platelets by antibodies against 
αIIbβ3 (Figure 1A). 
We report the case of a patient with severe bleeding diathesis associated with combined 
homozygous CalDAG-GEFI and heterozygous P2Y
12
 deficiencies (II-5, Figures 2A and 2B), 
characterized by normal ADP-induced platelet shape change but absent ADP-induced platelet 
aggregation. This is the first patient with combined CalDAG-GEFI and P2Y
12
 deficiencies that has 
been described so far. 
The following methods were employed: light transmission aggregometry in citrate-
anticoagulated PRP (patient II-1 [Figures 2A and 2B], who was first referred to our Center, was also 
studied by lumiaggregometry, which measures platelet aggregation and ATP secretion 
simultaneously); flow cytometry, to explore the expression of glycoproteins on the platelet 
membrane; PFA-100 and INNOVANCE PFA P2Y Closure Times; binding of P2Y
12
 antagonist 
[
3
H]PSB0413 to washed platelets, to calculate the number of P2Y
12
 binding sites;
8
 inhibition of 
prostaglandin (PG)E
1
-induced increase of cyclic adenosine monophosphate (cAMP) by ADP or 
epinephrine.
6
 
Genetic analyses were performed by Sanger sequencing of genomic DNA and cDNA from 
platelets after reverse transcriptase-polymerase chain reaction (RT-PCR), determination of P2RY12 
haplotypes and Whole Exome Sequencing. Details are included in Supplementary Materials. All 
diagnostic procedures were in accordance with the ethical standards of the responsible committee 
on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, 
as revised in 2008. All subjects gave their informed approval for all diagnostic procedures. 
Patient II-1 (Figures 2A and 2B) is a 31-year-old Italian woman with life-long easy bruising 
 4
and episodes of epistaxis, gum bleeding, otorrhagia, menorrhagia and excessive bleeding after 
tooth extractions (International Society on Thrombosis and Haemostasis Bleeding Score= 16; 
normal values <2). Platelet count and size were normal. Platelet aggregation induced by ADP, even 
at high concentrations (100 µM), was markedly reduced and rapidly reversible, suggesting a P2Y
12
 
defect (Figure 1C).
6
 The diagnostic suspicion was confirmed by the following findings: defective 
inhibition by ADP (but normal by epinephrine) of PGE
1
-induced increase in platelet cAMP (Figure 
1D), severe defect of binding sites for [
3
H]PSB0413 (Bmax=51 sites/platelet vs 425±50, mean±SD of 
10 controls), homozygous single base pair deletion (c.678delC, transcript ENST00000302632.3) in 
P2RY12-201 gene (Figures 2B and 2C), resulting in the p.T126 fs*34 (UniProtKB-Q9H244), expected 
to abrogate receptor function. Results of additional platelet studies were compatible with P2Y
12
 
deficiency: normal αIIbβ3 and GPIb/IX/V expression, normal platelet adenine nucleotides, 
serotonin and fibrinogen contents, partially defective platelet aggregation and secretion induced 
by secretion-stimulating agonists.
6
 Family studies revealed that the same mutation was present in 
homozygosity in her sister (II-2, with similar bleeding phenotype) and, in heterozygosity, in her 3 
first cousins (II-3, II-4, II-5) (Figure 2B). 
The personal bleeding history was negative for II-3 and II-4.
6
 However, it was positive and 
severe for II-5 (Figure 2A), despite her young age (9 years): in the first days of life she displayed 
purpuric lesions and suffered prolonged bleedings from the intramuscular injection sites of 
prophylactic vitamin K and vaccines, while in the first 2-3 years she suffered relapsing severe 
epistaxis that required hospitalizations and prolonged bleeding after the fall of a deciduous tooth. 
ADP-induced platelet aggregation was normal in II-3, slightly defective in II-4 and absent in II-5 
(Figure 1E), whose PFA-100 and INNOVANCE PFA P2Y Closure Times were extremely prolonged 
(>300 seconds). 
Based on these findings, we explored the possibility that II-5 carried additional defects of 
 5
platelet function. Extended P2RY12 genomic sequencing and haplotype analysis detailed the 
P2RY12 pattern (Figure 2D). The presence of an intronic mutation affecting mRNA expression
9 
was 
excluded by RT-PCR of platelet mRNA and cDNA sequencing. The heterozygous condition for the 
c.318C/T (Asn6) polymorphism (Figure2D, Supplementary Figure 1 and Supplementary Results) 
indicated the maternal inheritance of normal P2Y
12
 mRNA. Coexistent P2Y
1
 defect was ruled out 
based on the normality of platelet shape change and the normal sequence of P2RY1 gene 
(Supplementary Results). The type and severity of her platelet aggregation abnormality were 
apparently suggestive of a defect of integrin αIIbβ3 activation. Because Leukocyte Adhesion 
Deficiency-III could be safely ruled out based on the absence of predisposition to infections,
1
 we 
focused on Glanzmann Thrombasthenia and sequenced the ITGA2B and ITGB3 genes in platelet 
cDNAs, which revealed normal sequences characterized by polymorphic synonymous codons 
(Supplementary Results). Moreover, αIIbβ3 and other platelet glycoproteins were normally 
expressed on the patient’s platelets. 
We then turned to Whole Exome Sequencing for exploring the patient’s DNA, which 
revealed the presence of c.337delC mutation (transcript ENST00000354024.7, Figure 2E) in exon 5 
of RASGRP2-201 (encoding for CalDAG-GEFI), predicting a deleterious change in the protein 
(p.R113fs*6, UniProtKB-Q7LDG7), candidate to explain the phenotype. The mutation was 
confirmed in homozygosity by direct sequencing of the patient’s DNA, and in heterozygosity in II-1, 
II-3, II-4 (Figures 2Band 2E). 
In conclusion, patient II-5 displays an extremely severe defect of ADP-induced platelet 
aggregation, which is not attributable to defects in the final common steps of αIIbβ3 activation, as 
in Glanzmann Thrombasthenia or Leukocyte Adhesion Deficiency-III, but to combined homozygous 
CalDAG-GEFI and heterozygous P2Y
12
 deficiencies. The molecular defect of RASGRP2 causing 
CalDAG-GEFI deficiency in our patients is not present in The Genome Aggregation Database 
 6
(http://gnomad.broadinstitute.org/), while the P2Y
12
 defect has already been described in an 
unrelated family.
10
 Previous publications showed that patients with severe CalDAG-GEFI deficiency 
display partially defective ADP-induced platelet responses, characterized by normal shape change 
and irreversible or only partially reversible platelet aggregation of reduced amplitude.
11-14
 Based 
on the type and severity of the abnormality of platelet aggregation in patient II-5, we can infer 
that this pattern of platelet response to ADP in CalDAG-GEFI deficient patients would be explained 
by normal P2Y
1
-mediated platelet shape change, absent P2Y
1
/CalDAG-GEFI-mediated initial wave 
of fast platelet aggregation and normal (slow, incomplete and slowly reversible or irreversible) 
P2Y
12
-induced platelet aggregation (defective in patient II-5). Heterozygous P2Y
12
 deficiency is 
generally associated with abnormal, reversible platelet aggregation induced by ≤10 μM ADP
7
 (like 
in II-4), although our findings in II-3 suggest that the platelet aggregation defect is of variable 
severity in different patients. It is possible that the platelet aggregation defect in heterozygous 
P2Y
12
 deficiency is more evident in patients, like II-5, whose platelets lack the priming effect of 
P2Y
1
/CalDAG-GEFI. Interestingly, heterozygous CalDAG-GEFI deficiency did not appear to affect 
ADP-induced platelet aggregation significantly in the study subjects, when associated with both 
homozygous (II-1) and heterozygous (II-3, II-4) P2Y
12
 deficiency. It is interesting to note that, in our 
patients, compound homozygous CalDAG-GEFI and heterozygous P2Y
12
 deficiency (II-5) confers 
more severe abnormality of ADP-induced platelet aggregation and bleeding diathesis than 
compound homozygous P2Y
12
 and heterozygous CalDAG-GEFI deficiency (II-1). 
Unfortunately, the mother of patient II-5 did not give her consent to expose her daughter to 
additional blood sampling to allow the study of additional platelet functions and of leukocyte 
function. Indeed, deficiency of CalDAG-GEFI is expected to affect also leukocyte function, because 
Rap1 activation is important for leukocyte integrin activation.
15
 However, abnormal integrin-
dependent leukocyte function was shown to be defective in some, but not all CalDAG-GEFI-
 7
deficient patients. Despite the different results of in vitro experiments of leukocyte function, none 
of the patients who have been described so far, including our patient II-5, displayed overt immune 
defects, or susceptibility to bacterial infections, suggesting that alternative pathways of integrin 
activation in leukocytes compensate for CalDAG-GEFI deficiency. 
  
 8
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Figure Legends 
Figure 1. Pathophysiology of ADP-induced platelet function in normal subjects and in the studied 
patients. A – Effects of antagonists of P2Y
1
 (MRS2216, 25 μM), P2Y
12
 (AR-C69931MX, 1 μM) and 
αIIbβ3 (MoAb 10E5, 10 μg/ml) on ADP (5 μM)-induced platelet aggregation in platelet-rich plasma 
ADP
, 
added alone or in combination to normal platelet-rich plasma (PRP); maximal amplitude of 
platelet aggregation in control PRP (left tracing) was 78%; B - Regulation of ADP-induced platelet 
shape change and aggregation. ADP binding to Gq-coupled P2Y
1
 activates the PLCβ isoform, to 
form IP3, which releases Ca
2+
 from stores. Ca
2+
 induces: 1) platelet shape change through 
activation of MLCK and phosphorylation of myosin light chain (MLC); 2) platelet aggregation 
through rapid CalDAG-GEFI-dependent activation of the small GTPase Rap1 to Rap1-GTP, which, 
through the cooperation of talin and kindlin3 promotes the binding of adhesive proteins to αIIbβ3 
and platelet aggregation. This process is regulated by Ras GTPase-activating protein 3 (RASA3), 
which hydrolyses Rap1-GTP to inactive Rap1-GDP; RASA3 is inactivated by the Gi-coupled platelet 
ADP receptor P2Y
12
, allowing sustained Rap1 signalling and full platelet aggregation. PLCβ= 
phosphlipase Cβ; IP3= inositol trsiphosphate; MLCK= myosin light chain kinase; pMLC= 
phosphorylated myosin light chain; CalDAG-GEFI= calcium- and DAG-regulated guanine exchange 
factor-1; PI3K=phosphoinositide 3-kinase; DTS=dense tubular system; AC=adenylyl cyclase; 
cAMP=cyclic adenosine monophosphate; C - Platelet aggregation in citrate PRP from patient II-1 
(see Figure 2A and 2B) and a healthy control, induced by ADP at the indicated concentrations; 
maximal amplitude of platelet aggregation induced by ADP 10 μM was 80% in healthy control and 
15% in patient II-1; D – Effects of ADP and epinephrine, at the indicated concentrations, on PGE
1
 (1 
μM)-induced increase in platelet cAMP of II-1 and healthy controls (means±SD, n=21); E- Platelet 
aggregation in citrate PRP from patients II-3, II-4 and II-5 (see Figure 2A and 2B), induced by ADP at 
 12
the indicated concentrations; maximal amplitudes of platelet aggregation were 87% and 89% in II-
3 and 25% and 80% in II-4. 
Figure 2.  General characteristics and genetic abnormalities of the studied patients. A - Main 
characteristics of the study subjects (n.a.= not applicable); the two values of platelet count for 
patients II-1, II-2 and II-5 refer to values measured on two separate occasions; B - Upper part, 
pedigree chart. Filled symbols, subjects with bleeding diathesis. - Lower part, 
carriership/homozygosity for the P2RY12 and  RASGRP2 frameshift mutations; C - Chromatograms 
reporting the homozygous (II-1) and heterozygous (II-5) condition for the c.678delC frameshift 
mutation in the P2RY12 gene; D - P2RY12 haplotype analysis. Upper part, localization of SNPs in 
the P2RY12 genomic region. Primers for genomic DNA and cDNA amplification and sequencing are 
indicated by numbered arrows upper and below the scheme, respectively; numbering as reported 
in Supplementary Table 1; dotted arrows, position of gene alteration and informative SNPs. Lower 
part, haplotype marking of the c.678delC in the II generation. fs, frameshift; E- Chromatograms 
reporting the heterozygous (II-3) and homozygous (II-5) condition for the c.337delC frameshift 
mutation in the RASGRP2 gene. 
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Severe	bleeding	and	absent	ADP-induced	platelet	aggregation	
associated	with	inherited	combined	CalDAG-GEFI	and	P2Y12	deficiencies	
	
Supplementary	material	
Materials	
[3H]PSB-0413	was	from	General	Electric,	Healthcare	(Buckinghamshire,	UK).	ADP,	collagen,	the	
thromboxane/prostaglandin	endoperoxide	analogue	9,11-dideoxy-11,9-epoxymethano-
prostaglandin	F2	(U46619),	thrombin	receptor	activating	peptide	6	(TRAP-6),	prostaglandin	(PG)	E1,	
PGI2,	were	from	Sigma	(St.	Louis,	MO,	USA).	Apyrase	was	purified	from	potatoes.1	Commercial	
preparations	of	luciferin/luciferase	reagent	were	used	to	measure	the	platelet	ATP	and	ADP	
contents	(ATP	Assay	Kit,	BioOrbit	Oy,	Turku,	Finland),	and	platelet	secretion	concurrently	with	
platelet	aggregation	(Chronolume,	Chrono-log	Corp,	Havertown,	PA,	USA).	Serum	thromboxane	(Tx)	
B2	was	measured	by	a	commercially	available	enzymatic	immunoassay	(Thromboxane	B2	EIA	kit,	
Cayman	Chemical	Co.,	Ann	Arbor,	MI,	USA).	
	
Preparation	of	Platelet-Rich	Plasma	(PRP)	and	Washed	Platelet	Suspensions	
For	studies	with	PRP,	9	volumes	of	blood	were	drawn	into	1	volume	of	109	mmol/L	trisodium	
citrate,	and	then	centrifuged	at	200xg	for	10	min.	The	supernatant	PRP	was	transferred	into	a	clean	
plastic	tube;	the	platelet	counts	in	PRP	samples	were	not	adjusted	to	a	pre-defined	value.	For	the	
preparation	of	washed	platelet	suspensions,	6	volumes	of	blood	were	drawn	into	1	volume	of	acid-
citrate-dextrose	anticoagulant,	centrifuged	at	200xg	for	10	min	to	obtain	PRP,	which	was	used	to	
prepare	twice	washed	platelet	suspensions	in	Tyrode’s	buffer	containing	500	nmol/L	PGI2	during	the	
first	and	second	wash.	Platelet	counts	in	washed	platelet	suspensions	were	adjusted	to	3x1011/L.	
	
	 2	
Studies	of	Platelet	Aggregation	and	Secretion	
The	first	screening	of	platelet	aggregation	in	the	studied	patients	was	done	in	Florence,	suing	the	
platelet	aggregometer	APACT4004	(LABiTec®,	LAbor	BioMedical	Technologies	GmbH,	Ahrensburg,	
Germany).	Additional	studies	of	platelet	aggregation	in	patient	II-1	were	done	in	Milan,	where	
platelet	aggregation	and	secretion	were	studied	simultaneously	by	lumi-aggregometry.	Samples	of	
PRP	(0.45	mL)	were	incubated	with	50	µL	luciferine/luciferase	reagent	at	37	°C	for	30	sec	and	stirred	
at	1,000	rpm	in	a	lumi-aggregometer	(Lumi-aggregometer,	Chrono-log	Corp.,	Havertown,	PA,	USA).	
After	incubation,	10	µL	of	an	aggregating	agent	was	added	and	the	aggregation	and	ATP	secretion	
tracings	were	recorded	for	3	min. 
	
Binding	of	[3H]PSB-0413	to	Washed	Platelets	
Binding	experiments	were	performed	using	[3H]PSB-0413,	which	is	a	tritiated	derivative	of	a	
selective	nucleotide	antagonist	of	the	P2Y12R,	AR-C67085MX	(2-propylthioadenosine-5'-adenylic	
acid	(1,1-chloro-1-phosphonomethyl-1-phosphonylanhydride),	and	9x107	washed	platelets.	
Nonspecific	binding	was	defined	in	the	presence	of	1	mM	ADP.	Washed	platelets	were	incubated	
with	the	ligand	at	37°C	for	5	min;	then	bound	and	free	radioactivity	was	separated	by	filtration	
through	Whatman	GF/B	glass-fiber	filters.	Filters	were	then	washed	with	5x2	ml	of	ice	cold	washing	
buffer	(Tris	HCl	50	mM	pH	7.5,	EDTA	1	mM,	MgCl2	5	mM,	NaCl	100	mM).	Filter-bound	radioactivity	
was	counted	in	2	ml	liquid	scintillation	counter.	
	
Measurement	of	platelet	cAMP	
Platelet	cAMP	was	measured	by	a	radioisotopic	assay,	using	a	commercially	available	kit	(Cyclic	AMP	
[3H]	assay	system,	Amersham	International,	UK).	Duplicate	samples	of	1	mL	citrated	PRP	containing	
1	mM	theophylline	were	incubated	with	Tyrode’s	buffer	and	PGE1	(1	µM),	PGE1	and	ADP	or	
	 3	
epinephrine	(0.1	and	1.0	µM)	or	Tyrode’s	buffer	alone	in	a	control	mixture.	After	incubation	at	37	°C	
(2	min),	1	mL	of	5%	trichloroacetic	acid	was	added,	and	the	samples	were	snap-frozen	in	dry	ice	and	
methanol,	thawed	at	ambient	temperature,	and	then	shaken	at	4	°C	for	45	min.	After	centrifugation	
at	4	°C	for	30	min,	the	supernatant	was	extracted	three	times	with	5	mL	of	water-saturated	ether,	
dried	under	a	stream	of	nitrogen	at	60	°C,	and	stored	at	–20	°C.	Before	assay,	the	samples	were	
reconstituted	with	0.05	mol/L	Tris	buffer	containing	4	mmol/L	EDTA.	
	
Genetic	studies	
The		P2RY12	gene	(NCBI	Ref	Seq:	NG_016019.1)	was	genotyped	by	PCR	and	direct	sequencing	of	
the	three	exons	and	splicing	junctions,	of	1.1Kb	in	the	5’	gene	region,	0.64	Kb	of	intron	1	and	the	
whole	intron	2	(1.7Kb)	(Figure	2D).		Primer	sequences	and	position	are	shown	in	the	
Supplementary	Table	1.	Known	polymorphisms	were	identified,	which	permitted	the	definition	of	
P2RY12	haplotypes	in	the	family	(Figure	2D).	The	P2RY1	gene	was	amplified	and	sequenced	using	
the	forward	5’-CCCTGTTGTGTAAGCTCGGCG-3’	and	reverse	5’-	CTTTTTGAGCCGGCCCAGGG-3’	
primers,	and	the	forward	5’-CCATGTGTAAACTGCAGAGG-3’	and	5’-	CAAACAAGCTAAGTGTGGATG-
3’	primers.	Total	RNA	was	extracted	from	platelets	using	Tempus	Blood	RNA	Tubes	and	by	
Tempus	Spin	RNA	Isolation	Kit	(Applied	Biosystems,	Thermo	Fisher	Scientific,	Waltham,	MA	USA).	
The	P2RY12,	ITGB3	and	ITGA2B	mRNAs	were	reverse	transcribed	using	random	primers	and	the	
M-MLV	Reverse	Transcriptase	Kit	(Invitrogen,	Thermo	Fisher	Scientific,	Waltham,	MA	USA).	For	
P2RY12,	a	644	bp	cDNA	fragment,	spanning	exons	2-3,	was	amplified	with	primers	19	and	20	
(Supplementary	Table	1).	The	nested-PCR	fragment	(547	bp,	primers	21	and	22)	was	sequenced	
(Supplementary	Table	1).	The	cDNA	allelic	ratio	was	determined	by	densitometric	analysis	of	
chromatogram	peaks.	Evaluation	of	the	ratios	was	obtained	by	comparison	of	three	independent	
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nucleotide	sequences	and	normalization	for	flanking	C	and	T	peaks.	The	16	primers	for	ITGB3	and	
ITGA2B	cDNA	studies	are	available	on	request.	
We	performed	genetic	analysis	by	means	of	whole-exome	sequencing	(WES),	and	direct	DNA	
sequencing.	For	WES,	genomic	DNA	was	isolated	from	peripheral	blood	by	Wizard®	Genomic	DNA	
Purification	Kit	(Promega	Corporation,	Madison,	WI,	USA),	and	coding	regions	were	enriched	by	
using	SureSelectXT	Human	All	Exon	V5	kit	(50MB;	Agilent	Technologies).	DNA	sequencing	was	
undertaken	on	the	HiSeq2000	platform	(Illumina,	San	Diego,	CA,	USA)	with	125-bp	paired-end	
reads.	Mean	coverage	was	>95x	and	51	Megabases	was	the	target	size	that	required	∼4	Gigabases	
of	sequencing	per	sample.	Sequence	reads	were	aligned	to	the	human	genome	reference	sequence	
(GRCh37/hg19).	Exome	analysis	produced	a	large	number	of	variants	(~65.000	Single	Nucleotide	
Variations	and	~12.000	InDels).	Variant	annotation	(i.e.	exonic,	intronic,	UTRs;	for	exonic:	
synonymous,	nonsynonymous,	stop	gain/loss,	frameshift,	allele	frequency,	etc)	and	prioritization	
were	performed	using	an	open–source	software	(Variant	Studio,	Illumina).	To	minimize	the	number	
of	potentially	deleterious	gene	defects	different	approaches,	the	following	strategies	were	adopted:	
(i)	filtering	based	on	quality	score>30;	(ii)	excluding	variants	having	a	Minor	Allele	Frequency	(MAF)	
greater	than	0.01;	(iii)	removing	variants	outside	coding	regions	or	synonymous	coding	variants;	(iv)	
filtering	the	data	for	novelty	by	comparison	to	dbSNP	(http://www.ncbi.mln.nih.gov/snp),	Exome	
Aggregation	Consortium	(http://exac.broadinstitute.org/),	Exome	Variant	Server	
(http://evs.gs.washington.edu/EVS),	1000	Genomes	Projects	(http://browser.1000genomes.org),	
published	studies;		(v)	selecting	variants	that	segregate	according	to		the	presumed	pattern	of	
inheritance;	(vi)	querying	disease	databases,		such	as	ClinVar	(http://www.ncbi.nlm.nih.gov/clinvar),	
OMIM,	(http://www.omim.org),	HGMD	Locus-specific	database	(http://www.hgvs.org/).	After	these	
filtering	strategies,	the	number	of	variants	were	reduced	to~300-400.	To	further	prioritize	the	
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candidate	gene	defects,	a	functional	annotation	was	undertaken	based	on	effect	on	protein	
function	and	a	priori	knowledge	of	phenotype.		
After	this	initial	prioritization,	additional	strategies	were	used	to	find	the	causative	mutation:	
i.e.	the	linkage	strategy,	in	which	multiple	affected	family	members	were	sequenced	to	identify	
shared	variation	and,	in	addition,	unaffected	relatives	were	sequenced	to	exclude	a	benign	
variation;	the	overlap	strategy,	that	is	the	searching	for	mutation	in	multiple	unrelated	patients	with	
similar	phenotype.	Variants	were	validated	by	Sanger	sequencing	and	segregation	analysis	of	the	
prioritized	variants	was	performed	in	additional	affected	family	members	when	constitutive	DNA	
was	available.	
Supplementary	Results	
The	intron	less	P2RY1	gene	(coding	sequence,	1122bp)	sequencing	detected	only	previously	
reported	synonymous	codons	(Ala19Ala,	rs1065776	C/T	and	Val262Val,	rs701265	A/G),	in	the	
homozygous	condition	(CC	and	AA,	respectively)	in	the	patient	II-5	and	in	the	heterozygous	form	in	
her	mother	(I-4)	and	brother	(II-4).	
The	P2RY12	mRNA	extracted	from	platelets	of	the	patient	II-5,	heterozygous	for	the	c.318C/T	
polymorphism	and	the	c.678delC	frameshift	mutation,	was	studied.	The	cDNA	allelic	ratio	was	
estimated	at	the	c.618C/T	position	through	the	peak	area	in	the	chromatograms	derived	from	two	
independent	RT-PCR	and	sequencing.	The	cDNA	corresponding	to	the	alleles	318T	and	318C,	which	
marks	the	c.678delC	and	thus	the	translational	frameshift,	were	similarly	represented	(T/C	ratio	
0.77-1.27,	Supplementary	Figure	1).	The	nonsense	mediated	decay	(NMD)	mechanism	is	not	
expected	to	alter	this	ratio	because	of	the	introduction	of	a	premature	nonsense	triplet	in	the	last	
exon.	Sequencing	of	the	coding	portion	of	exon	3	(1	Kb)	in	the	cDNA	failed	to	detect	any	additional	
mutation.	
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The	ITGB3	and	ITGA2B	mRNA	were	characterized	by	sequencing	of	the	ITGB3	and	ITGA2B	
platelet	cDNAs	in	the	patient	II-5.	Only	previously	described	ITGB3	synonymous	polymorphisms	
(Val381Val,	rs15908	A/C,	Glu511Glu	rs4642	A/G	and	Arg515Arg	rs4634	G/A)	were	detected	in	the	
heterozygous	condition.	
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Supplementary	Table	1.	P2RY12	primer	sequence	and	position.	
Primer	 Primer	sequence	(5’-	3’)	 Position	a	
		1	 ACTTTCTGATCGCTTGTCTCC	 4698	
		2	 AACTCTATGCTTGGACTGGC	 5244	
		3	 TTCTCAGCCATCCTCATCCC	 48839	
		4	 TGAGGCAAAGTAACTAAGACCA	 49416	
		5	 GTGCTTTAAGAGGCAAACATTCA	 50622	
		6	 TGCCAGACTAGACCGAACTC	 51471	
		7	 TCTCTGTTGTCATCTGGGCA	 51342	
		8	 TGTCGTTTGTTTTGCTGCTAA	 52170	
		9	 GAATGTCGGTGGTTGCTTACTG	 3842	
10	 AGGCATATGCTTGTCTTCTAAG	 4452	
11	 TTCAGGGAAACATTTTAAGTCC	 4339	
12	 ATTGTGATCACTACCCTGGA	 5008	
13	 GGAAGCTGTTTCACCTACAAAG	 48473	
14	 TCAGTAAAGTCTTGAGTGCTC	 49016	
15	 AATACCAGATGCCACTCTGC	 49081	
16	 ATTGGCCTCACGGAGATTCA	 50249	
17	 GGAATGCCAACTCATGACCA	 50056	
18	 CGCCAGGCCATTTGTGATAA	 51049	
19	 CCACTCTGCAGGTTGCAATAAC	 49092	
20	 TGCCAGACTAGACCGAACTC	 51471	
21	 GATACATTCAAACCCTCCAGAATC	 49126	
22	 TGCCTGTTGGTCAGAATCATGT	 51408	
Grey	lines,	forward	primers;	white	lines,	reverse	primers.	Primers	1-8,	primers	used	to	amplify	and	
sequence	exons	and	splicing	junctions	of	the	P2RY12	gene;	primers	9-18,	primers	used	for	the	5’	
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and	intronic	regions;	primers	19-22,	primers	for	the	cDNA.	a	Corresponding	to	the	position	of	the	5’	
end	in	the	sequence	database.	
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Supplementary	Figure	1	-	Chromatograms	of	the	exonic	nucleotide	change	c.318C/T	(patient	II-5)	in	
the	genomic	DNA	(upper	panel)	and	platelet	cDNA	(lower	panel).	
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